Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EPS (Weighted Average and Diluted) (2021 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.03 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 150.0% year-over-year to -$0.03, compared with a TTM value of -$0.18 through Dec 2025, up 30.77%, and an annual FY2025 reading of -$0.09, up 80.43% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.03 for Q4 2025 at Neuroone Medical Technologies, up from -$0.04 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.06 in Q4 2024 and bottomed at -$0.25 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.13 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 142.86% in 2024, then crashed 150.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.18 in 2021, then skyrocketed by 41.41% to -$0.11 in 2022, then crashed by 31.14% to -$0.14 in 2023, then skyrocketed by 142.86% to $0.06 in 2024, then plummeted by 150.0% to -$0.03 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NMTC at -$0.03 in Q4 2025, -$0.04 in Q3 2025, and -$0.04 in Q2 2025.